These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11298622)

  • 1. Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma.
    Mels AK; Statius Muller MG; van Leeuwen PA; von Blomberg BM; Scheper RJ; Cuesta MA; Beelen RH; Meijer S
    Br J Surg; 2001 Apr; 88(4):539-44. PubMed ID: 11298622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative sargramostim (recombinant human GM-CSF) induces an increase in the level of soluble VEGFR1 in colon cancer patients undergoing minimally invasive surgery.
    Kirman I; Belizon A; Balik E; Feingold D; Arnell T; Horst P; Kumara S; Cekic V; Jain S; Nasar A; Whelan RL
    Eur J Surg Oncol; 2007 Dec; 33(10):1169-76. PubMed ID: 17512160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte-macrophage colony-stimulating factor (GM-CSF) restores decreased monocyte HLA-DR expression after cardiopulmonary bypass.
    Börgermann J; Friedrich I; Scheubel R; Kuss O; Lendemans S; Silber RE; Kreuzfelder E; Flohé S
    Thorac Cardiovasc Surg; 2007 Feb; 55(1):24-31. PubMed ID: 17285470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential immunostimulating effect of granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF) and interferon gamma (IFNgamma) after severe trauma.
    Lendemans S; Kreuzfelder E; Waydhas C; Schade FU; Flohé S
    Inflamm Res; 2007 Jan; 56(1):38-44. PubMed ID: 17334669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Granulocyte-macrophage colony-stimulating factor stimulates human monocyte accessory cell function.
    Smith PD; Lamerson CL; Wong HL; Wahl LM; Wahl SM
    J Immunol; 1990 May; 144(10):3829-34. PubMed ID: 2185314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma.
    Flohé S; Lendemans S; Selbach C; Waydhas C; Ackermann M; Schade FU; Kreuzfelder E
    Crit Care Med; 2003 Oct; 31(10):2462-9. PubMed ID: 14530752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative granulocyte/macrophage colony-stimulating factor (GM-CSF) increases hepatic dendritic cell numbers and clustering with lymphocytes in colorectal cancer patients.
    Oosterling SJ; Mels AK; Geijtenbeek TB; van der Bij GJ; Tuk CW; Vuylsteke RJ; van Leeuwen PA; Meijer GA; Meijer S; Beelen RH; van Egmond M
    Immunobiology; 2006; 211(6-8):641-9. PubMed ID: 16920503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effect of granulocyte-macrophage colony-stimulating factor and interferon combination on monocyte-macrophage and T-lymphocyte functions in chronic hepatitis B leukocytopenic patients.
    Kountouras J; Boura P; Tsapas G
    Hepatogastroenterology; 1998; 45(24):2295-302. PubMed ID: 9951912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of recombinant human granulocyte macrophage colony-stimulating factor in the management of radiotherapy-induced esophagitis.
    Koukourakis MI; Flordellis CS; Giatromanolaki A; Koukouraki S; Kapsoritakis A; Potamianos S; Retalis G; Sivridis E; Salsaa B; Harris AL; Maragoudakis MI
    Clin Cancer Res; 1999 Dec; 5(12):3970-6. PubMed ID: 10632327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF.
    Schmid I; Baldwin GC; Jacobs EL; Isacescu V; Neagos N; Giorgi JV; Glaspy JA
    Cytometry; 1995 Jun; 22(2):103-10. PubMed ID: 7587740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and humoral inflammatory response after laparoscopic and conventional colorectal resections.
    Ordemann J; Jacobi CA; Schwenk W; Stösslein R; Müller JM
    Surg Endosc; 2001 Jun; 15(6):600-8. PubMed ID: 11591950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.
    van Royen N; Schirmer SH; Atasever B; Behrens CY; Ubbink D; Buschmann EE; Voskuil M; Bot P; Hoefer I; Schlingemann RO; Biemond BJ; Tijssen JG; Bode C; Schaper W; Oskam J; Legemate DA; Piek JJ; Buschmann I
    Circulation; 2005 Aug; 112(7):1040-6. PubMed ID: 16087795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
    Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
    Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
    Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
    Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
    Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
    J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock.
    Pangault C; Le Tulzo Y; Tattevin P; Guilloux V; Bescher N; Drénou B
    Crit Care Med; 2006 Apr; 34(4):1193-201. PubMed ID: 16484916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients.
    Barrio MM; de Motta PT; Kaplan J; von Euw EM; Bravo AI; Chacón RD; Mordoh J
    J Immunother; 2006; 29(4):444-54. PubMed ID: 16799340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
    Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
    Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mouth-washings with recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) do not improve grade III-IV oropharyngeal mucositis (OM) in patients with hematological malignancies undergoing stem cell transplantation. Results of a randomized double-blind placebo-controlled study.
    Valcárcel D; Sanz MA; Sureda A; Sala M; Muñoz L; Subirá M; Laborda R; Clopés A; Sierra J
    Bone Marrow Transplant; 2002 May; 29(9):783-7. PubMed ID: 12040477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
    Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
    J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.